Large-cell neuroendocrine cancer of the colon following rituximab-based lymphoma treatment

Hugh J Freeman MD FRCP, Peter WC Kwan MD FRCP, Douglas Webber MD FRCP

A 58-year-old man was referred in June 1991 with rectal bleeding for a colonoscopy that showed a sigmoid adenocarcinoma. Anterior resection revealed extension into, but not through, the muscularis propria, as well as 18 benign lymph nodes. Annual colonoscopies were performed for five years, then every three years. In 2002, he underwent prostatectomy for prostate carcinoma. In 2008, a stage IVA, diffuse large B-cell right testicular lymphoma was treated with right orchidectomy, scrotal radiation and six cycles of CHOP-R (cyclophosphamide-doxorubicin-vincristine-prednisolone-rituximab).

In 2008, colonoscopy and computed tomography (CT) scans of the head, abdomen and pelvis were normal, with no evidence of lymphoma. While travelling in southern France and Spain in June 2011, he developed abdominal pain and diarrhea for three days. This resolved for approximately one week and then recurred over a two-week period after his return to Canada. His physical examination was normal and laboratory studies revealed a mild anemia (hemoglobin level 122 g/L), but a normal white blood cell count and no left shift or eosinophilia. Fecal studies for bacteria and parasites were negative. A CT scan showed circumferential thickening of the hepatic flexure along with hepatic hypodense lesions, and colonoscopy showed an obstructing carcinoma. A right hemicolecetomy and partial hepatectomy revealed a large cell neuroendocrine carcinoma invading through the colonic wall and involving seven of 14 regional lymph nodes and the liver. Microscopic evaluation showed predominately trabecular and insular architecture; the nests comprised of relatively monomorphous, but large cells, with moderate amounts of cytoplasm, an open nuclear chromatin pattern and a high mitotic apoptotic rate (Figure 1). Immunohistochemical staining for synaptophysin was strongly positive (Figure 2). Chromogranin was also positive. Subsequent chemotherapy treatment included carboplatin and etoposide.

**DISCUSSION**

This patient developed four primary malignancies over two decades, including a highly aggressive and poorly differentiated large cell neuroendocrine carcinoma of the colon. These unusual cancers accounted for less than 1% of all colorectal malignancies reported over more than a decade from Memorial Sloan-Kettering in New York (USA) (1) and are distinct from well-differentiated carcinoid tumours (or neuroendocrine tumours using the WHO schema). Neuroendocrine carcinomas can be further subdivided into small and large cell types based on their histological and immunohistological features, and most stain positively for markers such as synaptophysin and chromogranin (1). Approximately 70% of neuroendocrine carcinomas present with metastatic disease and are associated with a dismal prognosis, with a reported mean survival of approximately 10 months (1). In spite of scheduled surveillance examinations for dysplasia in high-risk populations, such as long-standing ulcerative colitis (2), highly aggressive neuroendocrine carcinomas have been documented. In some patients, combination platinum and etoposide therapy has been associated with long-term survival (3).

---

1Departments of Medicine (Gastroenterology) and 2Pathology, University of British Columbia, Vancouver, British Columbia

Correspondence: Dr Hugh J Freeman, University of British Columbia Hospital (Gastroenterology), 2211 Wesbrook Mall, Vancouver, British Columbia V6T 1W5. Telephone 604-822-7216, fax 604-822-7236, e-mail hugfree@shaw.ca

Received for publication April 4, 2010. Accepted April 14, 2010
Many anticancer agents have been shown to be carcinogenic, mutagenic and teratogenic in animal and in vitro test systems, while epidemiological studies have noted the association of second neoplasms with specific chemotherapy agents (4). Human exposure has also been a concern, particularly as an occupational exposure in the manufacture, preparation and administration of anticancer agents, including medical staff (4). Recently, concerns have also been expressed regarding the development of malignancies after rituximab, a CD20 monoclonal antibody that has been used effectively in the treatment of B-cell lymphoma (5). In 26 previously reported cases of a second malignancy after initiation of rituximab treatment, the median time period was five months with a range of one to 40 months (5). Further follow-up studies of patients treated with these regimens are needed.

REFERENCES